This study is a pharmacokinetic (PK) and pharmacodynamics (PD) approach using betahistine doses levels in unilateral vestibular neurectomized cats (UVN) comparable to those used in humans for treating patients with Menière's disease. The aim is to investigate for the first
The Libyan journal of medicine, 15(1), 1808361-1808361 (2020-08-19)
The administration of therapeutic agents is difficult in many patients, such as patients with post-operative delirium or dementia or patients with schizophrenia, who are upset in an emergency room. Therefore, the development of a new method for administering therapeutic agents
Betahistine is a histamine analogue that is used for the treatment of Menière's disease. Animal studies showed that it increases local blood flow in the stria vascularis. In terms of its mode of action, recent studies have prompted discussion of
Brazilian journal of otorhinolaryngology, 79(3), 366-374 (2013-06-08)
Virtual reality technology can provide a wide range of sensory stimuli to generate conflicts of varying degrees of complexity in a safe environment. To verify the effect of a virtual realitybased balance rehabilitation program for patients with Menière's disease. This
Combination treatment with reboxetine, a selective norepinephrine reuptake inhibitor, and betahistine, a histamine H1 receptor agonist/H3 antagonist, was developed to produce complementary action in CNS pathways regulating appetite and body weight. In the present placebo-controlled study, we evaluated whether a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
![2-[(Methylamino)methyl]pyridine 97%](/deepweb/assets/sigmaaldrich/product/structures/370/687/248fbc0c-2e59-447c-8191-2685dfb597d6/640/248fbc0c-2e59-447c-8191-2685dfb597d6.png)
